Thoracic endografting is an evolving modality for thoracic aortic diseases, with upcoming technological refinements expected to improve safety and deliverability.
Unmet needs persist in thoracic endografting; leaves open whether next-generation devices will improve clinical outcomes.
Endovascular repair has emerged as a very important treatment modality in the management of a host of serious and relatively frequent thoracic aortic diseases. This minimally invasive approach is certain to revolutionize the entire field of thoracic aortic surgery in the near future. The technologies, however, can still be considered as a "work in progress." Future refinements, which should be available within the next 1 to 2 years, will address some of the most important needs as yet unmet today: lower profile (<22 F) delivery systems, greater device flexibility, no longitudinal metal bars, and precise deliverability and deployment characteristics that will be conducive to optimal success and safety, especially in the region of the aortic arch.
No takes yet. Share an insight, caveat, or question.
Abul-Khoudoud et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: